{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T05:12:41Z","timestamp":1777957961875,"version":"3.51.4"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.psychres.2025.116490","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T19:01:36Z","timestamp":1744398096000},"page":"116490","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Efficacy and tolerability of esmethadone in patients with major depressive disorder: A meta-analysis of 3 randomized controlled trials"],"prefix":"10.1016","volume":"348","author":[{"given":"Lanlan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daocheng","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengzhong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.psychres.2025.116490_bib0042","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s40263-023-01032-5","article-title":"Dextromethorphan-bupropion for the treatment of depression: a systematic review of efficacy and safety in clinical trials","volume":"37","author":"Akbar","year":"2023","journal-title":"CNS. Drugs"},{"key":"10.1016\/j.psychres.2025.116490_bib0009","article-title":"The American psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia [Internet]","year":"2016","journal-title":"American Psychiatric Association"},{"key":"10.1016\/j.psychres.2025.116490_bib0025","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/JCP.0000000000001035","article-title":"Characterization of the safety and pharmacokinetic profile of d-methadone, a novel N-methyl-d-aspartate receptor antagonist in healthy, opioid-naive subjects: results of two phase 1 studies","volume":"39","author":"Bernstein","year":"2019","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.psychres.2025.116490_bib0017","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/nrn1846","article-title":"New approaches to antidepressant drug discovery: beyond monoamines","volume":"7","author":"Berton","year":"2006","journal-title":"Nat. Rev. Neurosci. Nat. Publ. Group;"},{"key":"10.1016\/j.psychres.2025.116490_bib0021","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1176\/appi.ajp.2018.17060720","article-title":"Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study","volume":"175","author":"Canuso","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.psychres.2025.116490_bib0032","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis","volume":"391","author":"Cipriani","year":"2018","journal-title":"The Lancet"},{"key":"10.1016\/j.psychres.2025.116490_bib0005","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1001\/jamapsychiatry.2020.0164","article-title":"Psychotherapy for depression across different age groups: a systematic review and meta-analysis","volume":"77","author":"Cuijpers","year":"2020","journal-title":"JAMa Psychiatry"},{"key":"10.1016\/j.psychres.2025.116490_bib0037","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.671859","article-title":"REL-1017 (Esmethadone) increases circulating BDNF levels in healthy subjects of a phase 1 clinical study","volume":"12","author":"De Martin","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.psychres.2025.116490_bib0026","doi-asserted-by":"crossref","DOI":"10.1176\/appi.ajp.2021.21020197","article-title":"REL-1017 (Esmethadone) as adjunctive treatment in patients with major depressive disorder: a phase 2a randomized double-blind trial","author":"Fava","year":"2022","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.psychres.2025.116490_bib0024","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1007\/s00406-023-01571-4","article-title":"Esmethadone-HCl (REL-1017): a promising rapid antidepressant","volume":"273","author":"Fava","year":"2023","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.psychres.2025.116490_bib0031","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.24m15265","article-title":"Efficacy and safety of Esmethadone (REL-1017) in patients with major depressive disorder and inadequate response to standard antidepressants: a phase 3 randomized controlled trial","author":"Fava","year":"2024","journal-title":"J. Clin. Psychiatry [Internet]"},{"key":"10.1016\/j.psychres.2025.116490_bib0036","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s40268-024-00477-3","article-title":"Pharmacokinetics, tolerability, and safety of Esmethadone in subjects with chronic kidney disease or hepatic impairment","volume":"24","author":"Ferri","year":"2024","journal-title":"Drugs R. D."},{"key":"10.1016\/j.psychres.2025.116490_bib0006","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/S2215-0366(20)30130-9","article-title":"Efficacy of cognitive bias modification interventions in anxiety and depressive disorders: a systematic review and network meta-analysis","volume":"7","author":"Fodor","year":"2020","journal-title":"The Lancet Psychiatry. Elsevier"},{"issue":"392","key":"10.1016\/j.psychres.2025.116490_bib0001","first-page":"1789","volume":"2018","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.psychres.2025.116490_bib0012","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1017\/S1092852921000791","article-title":"Novel antidepressant drugs: beyond monoamine targets","volume":"28","author":"Gonda","year":"2023","journal-title":"CNS. Spectr."},{"key":"10.1016\/j.psychres.2025.116490_bib0029","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.psychres.2025.116490_bib0019","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1085\/jgp.201812032","article-title":"Structure, function, and allosteric modulation of NMDA receptors","volume":"150","author":"Hansen","year":"2018","journal-title":"J. Gen. Physiol."},{"key":"10.1016\/j.psychres.2025.116490_bib0028","series-title":"Cochrane Handbook for Systematic Reviews of Interventions [Internet]","author":"Higgins","year":"2008"},{"key":"10.1016\/j.psychres.2025.116490_bib0022","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/ijnp\/pyaa068","article-title":"Esketamine nasal spray for rapid reduction of depressive symptoms in patients with major depressive disorder who have active suicide ideation with intent: results of a phase 3, double-blind, randomized study (ASPIRE II)","volume":"24","author":"Ionescu","year":"2021","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.psychres.2025.116490_bib0040","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.21m14345","article-title":"Efficacy and safety of AXS-05 (Dextromethorphan-Bupropion) in patients with major depressive disorder: a phase 3 randomized clinical trial (GEMINI)","volume":"83","author":"Iosifescu","year":"2022","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psychres.2025.116490_bib0038","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1176\/appi.ajp.20230025","article-title":"Pharmacotherapies for treatment-resistant depression: how antipsychotics fit in the rapidly evolving therapeutic landscape","volume":"180","author":"Jha","year":"2023","journal-title":"AJP"},{"key":"10.1016\/j.psychres.2025.116490_bib0007","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1001\/jamapsychiatry.2020.4364","article-title":"Internet-based cognitive behavioral therapy for depression: a systematic review and Individual patient Data network meta-analysis","volume":"78","author":"Karyotaki","year":"2021","journal-title":"JAMa Psychiatry"},{"key":"10.1016\/j.psychres.2025.116490_bib0002","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1146\/annurev.publhealth.29.020907.090847","article-title":"The descriptive epidemiology of commonly occurring mental disorders in the United States","volume":"29","author":"Kessler","year":"2008","journal-title":"Annu. Rev. Public Health"},{"key":"10.1016\/j.psychres.2025.116490_bib0004","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1001\/jama.289.23.3095","article-title":"The epidemiology of major depressive disorder: results from the national comorbidity survey replication (NCS-R)","volume":"289","author":"Kessler","year":"2003","journal-title":"JAMa"},{"key":"10.1016\/j.psychres.2025.116490_bib0018","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.genhosppsych.2015.01.003","article-title":"Ketamine as a novel treatment for major depressive disorder and bipolar depression: a systematic review and quantitative meta-analysis","volume":"37","author":"Lee","year":"2015","journal-title":"Gen. Hosp. Psychiatry"},{"key":"10.1016\/j.psychres.2025.116490_bib0034","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41380-023-02353-z","article-title":"Unique pharmacodynamic properties and low abuse liability of the \u00b5-opioid receptor ligand (S)-methadone","volume":"29","author":"Levinstein","year":"2024","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.psychres.2025.116490_bib0027","first-page":"e1","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"Epidemiol. Biostat. Public Health."},{"key":"10.1016\/j.psychres.2025.116490_bib0016","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.tips.2023.06.009","article-title":"GABAA receptors as targets for treating affective and cognitive symptoms of depression","volume":"44","author":"Luscher","year":"2023","journal-title":"Trends. Pharmacol. Sci."},{"key":"10.1016\/j.psychres.2025.116490_bib0011","doi-asserted-by":"crossref","first-page":"946","DOI":"10.4088\/JCP.v69n0610","article-title":"Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder","volume":"69","author":"Machado-Vieira","year":"2008","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psychres.2025.116490_bib0020","doi-asserted-by":"crossref","unstructured":"Machado-Vieira R., Salvadore G., Ibrahim L.A., Diaz-Granados N., Jr C.A.Z. Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders. Curr. Pharm. Des.. 2009;15:1595\u2013611.","DOI":"10.2174\/138161209788168010"},{"key":"10.1016\/j.psychres.2025.116490_bib0014","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.pneurobio.2015.12.001","article-title":"New targets for rapid antidepressant action","volume":"152","author":"Machado-Vieira","year":"2017","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.psychres.2025.116490_bib0039","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s40263-018-0519-3","article-title":"Antidepressant efficacy and tolerability of ketamine and esketamine: a critical review","volume":"32","author":"Molero","year":"2018","journal-title":"CNS. Drugs"},{"key":"10.1016\/j.psychres.2025.116490_bib0035","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1038\/s41380-024-02621-6","article-title":"Letter to the editor regarding \u201cunique pharmacodynamic properties and low abuse liability of the \u00b5-opioid receptor ligand (S)-methadone","volume":"29","author":"Pappagallo","year":"2024","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.psychres.2025.116490_bib0023","doi-asserted-by":"crossref","DOI":"10.1176\/appi.ajp.2019.19020172","article-title":"Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study","author":"Popova","year":"2019","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.psychres.2025.116490_bib0013","doi-asserted-by":"crossref","first-page":"148","DOI":"10.4088\/JCP.v66n0201","article-title":"Is there a delay in the antidepressant effect? A meta-analysis","volume":"66","author":"Posternak","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psychres.2025.116490_bib0030","unstructured":"Relmada Therapeutics, Inc. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of REL-1017 Monotherapy for Major Depressive Disorder [Internet]. clinicaltrials.gov; 2024 Mar. Report No.: NCT05081167. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05081167."},{"key":"10.1016\/j.psychres.2025.116490_bib0033","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41398-023-02473-8","article-title":"The novel uncompetitive NMDA receptor antagonist esmethadone (REL-1017) has no meaningful abuse potential in recreational drug users","volume":"13","author":"Shram","year":"2023","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.psychres.2025.116490_bib0015","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232012196","article-title":"Esmethadone (REL-1017) and other uncompetitive NMDAR channel blockers may improve mood disorders via modulation of synaptic kinase-mediated signaling","volume":"23","author":"Stahl","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.psychres.2025.116490_bib0041","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1176\/appi.ajp.21080800","article-title":"Effect of AXS-05 (Dextromethorphan-Bupropion) in major depressive disorder: a randomized double-blind controlled trial","volume":"179","author":"Tabuteau","year":"2022","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.psychres.2025.116490_bib0010","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1177\/104012371402600310","article-title":"Defining treatment-resistant depression: a comprehensive review of the literature","volume":"26","author":"Trevino","year":"2014","journal-title":"Ann. Clin. Psychiatry"},{"issue":"319","key":"10.1016\/j.psychres.2025.116490_bib0003","first-page":"1444","article-title":"The State of US health, 1990-2016: burden of diseases, injuries, and risk factors among US states","author":"Mokdad","year":"2018","journal-title":"JAMa"},{"key":"10.1016\/j.psychres.2025.116490_bib0008","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.20m13699","article-title":"The prevalence and national burden of treatment-resistant depression and major depressive disorder in the United States","volume":"82","author":"Zhdanava","year":"2021","journal-title":"J. Clin. Psychiatry"}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178125001386?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178125001386?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T04:32:44Z","timestamp":1777955564000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178125001386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":42,"alternative-id":["S0165178125001386"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2025.116490","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and tolerability of esmethadone in patients with major depressive disorder: A meta-analysis of 3 randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2025.116490","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116490"}}